DNAprint Genomics (DNAG)

[DougS.]

w2p - since I started reading about Moffitt and what they do, I've seen a lot of new studies that aim to predict patient response through hybrid approaches. I like this idea. It could really speed things up.

If DNAP could explain, say, only 70% of the variability in patient response and Moffit can explain say, only 70% as well - together they could conceivably explain >95% if they did not completely overlap. But portions of findings that are overlapping or redundant in their predictivity might be able to bolster an FDA application. As long as their independent research is somewhat complimentary it's a win-win situation, IMO.

If new studies are anything like the Ovanome project which already had greater than 95% predictivity in the first screen, they could develop very accurate classifiers and possibly much faster than if DNAP were to do it on their own.

I'm still sceptical of the Affymetrix connection. Some of their technology still seems to be in competition with ours. But we'll see about that